This rare insertion has been identified in three Japanese families with disorders in the frontotemporal dementia (FTD) spectrum, although some members have been diagnosed with Parkinson’s disease (PD) ...

Good managers set the tone for the whole team, encouraging positive behavior from everyone around them. In the November 5 Nature, scientists introduce a subtype of microglia that appears to do just ...

Cerebrovascular disease commonly occurs alongside Alzheimer’s. The two share some pathological features, such as leakiness of the blood-brain barrier. Do they share genetic drivers, too? No, according ...

The App SAA mouse joins a list of knock-in models that carry a humanized Aβ sequence within the murine App gene (App knock-in (humanized Aβ), APP NL-F Knock-in, APP NL-G-F Knock-in). As in the latter ...

Hypertension heightens the risk of Alzheimer’s disease, but exactly how is not understood. In a bioRxiv preprint posted September 19, scientists led by Costantino Iadecola at Weill Cornell Medical ...

Background Acute administration of nicotine to AD patients improved accuracy of delayed recall, as well as deficits in attention and information processing (Sahakian et al. 1989; Wesnes and Warburton, ...

neuronal cell bodies, dendrites and some thick axonsin the central and peripheral nervous systems, but not thin axons;reflects extent of aberrant phosphorylation of neurofilaments in ...

These mice have a targeted deletion in the mouse gene β-site APP cleaving enzyme 1 (BACE1). Homozygous mice are viable, fertile, normal in size, and do not display any gross physical or behavioral ...

This APP transgenic overexpresses mutant human APP under the control of the Thy-1.2 promoter, driving neuronal expression. The transgene carries two mutations associated with familial Alzheimer’s ...

Building 114, Suite 2011 16th Street Charlestown, MA02129 United States Visit Website Contact: Bradley T. Human, M.D., Ph.D. Phone: (617) 726-3987 E-mail: [email protected] Brain Banks Home ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...